Overall, the majority of NK cell-based immunotherapy investigations have centered around HER2+ breast cancer as HER2-targeting monoclonal antibodies work, in part, through antibody-dependent cellular cytotoxicity, of which NK cells play a crucial role (115). This evidence concerns the gene ERBB2 and breast carcinoma.